Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 5/2016

19.12.2015 | Original Article

Occupational radiation exposure of medical staff performing 90Y-loaded microsphere radioembolization

verfasst von: Sophie Laffont, Yan Rolland, Valérie Ardisson, Julien Edeline, Marc Pracht, Samuel Le Sourd, Tanguy Rohou, Laurence Lenoir, Nicolas Lepareur, Etienne Garin

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Radioembolization of liver cancer with 90Y-loaded microspheres is increasingly used but data regarding hospital staff exposure are scarce. We evaluated the radiation exposure of medical staff while preparing and injecting 90Y-loaded glass and resin microspheres especially in view of the increasing use of these products.

Methods

Exposure of the chest and finger of the radiopharmacist, nuclear medicine physician and interventional radiologist during preparation and injection of 78 glass microsphere preparations and 16 resin microsphere preparations was monitored. Electronic dosimeters were used to measure chest exposure and ring dosimeters were used to measure finger exposure.

Results

Chest exposure was very low for both products used (<10 μSv from preparation and injection). In our experience, finger exposure was significantly lower than the annual limit of 500 mSv for both products. With glass microspheres, the mean finger exposure was 13.7 ± 5.2 μSv/GBq for the radiopharmacist, and initially 17.9 ± 5.4 μSv/GBq for the nuclear medicine physician reducing to 13.97 ± 7.9 μSv/GBq with increasing experience. With resin microspheres, finger exposure was more significant: mean finger exposure for the radiopharmacist was 295.1 ± 271.9 μSv/GBq but with a reduction with increasing experience to 97.5 ± 35.2 μSv/GBq for the six most recent dose preparations. For administration of resin microspheres, the greatest mean finger exposure for the nuclear medicine physician (the most exposed operator) was 235.5 ± 156 μSv/GBq.

Conclusion

Medical staff performing 90Y-loaded microsphere radioembolization procedures are exposed to safe levels of radiation. Exposure is lower than that from treatments using 131I-lipiodol. The lowest finger exposure is from glass microspheres. With resin microspheres finger exposure is acceptable but could be optimized in accordance with the ALARA principle, and especially in view of the increasing use of radioembolization.
Literatur
1.
Zurück zum Zitat Salem R, Lewandowski RJ, Mulcahy MF, Wang E, Riaz A, Ryu RK, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.CrossRefPubMed Salem R, Lewandowski RJ, Mulcahy MF, Wang E, Riaz A, Ryu RK, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.CrossRefPubMed
2.
Zurück zum Zitat Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–78.CrossRefPubMed Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–78.CrossRefPubMed
3.
Zurück zum Zitat Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711–20.CrossRefPubMed Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711–20.CrossRefPubMed
4.
Zurück zum Zitat Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057–68.CrossRefPubMedPubMedCentral Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057–68.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Bernal P, Raoul JL, Stare J, Sereegotov E, Sundram FX, Kumar A, et al. International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study. Semin Nucl Med. 2008;38(2):S40–5.CrossRefPubMed Bernal P, Raoul JL, Stare J, Sereegotov E, Sundram FX, Kumar A, et al. International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study. Semin Nucl Med. 2008;38(2):S40–5.CrossRefPubMed
6.
Zurück zum Zitat Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Mali WP, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13(10):1025–34.CrossRefPubMed Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Mali WP, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13(10):1025–34.CrossRefPubMed
7.
Zurück zum Zitat Gibbs P, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Gebski V, et al. 2015 ASCO Annual Meeting. J Clin Oncol. 2015;33 (Suppl). Abstract 3502. Gibbs P, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Gebski V, et al. 2015 ASCO Annual Meeting. J Clin Oncol. 2015;33 (Suppl). Abstract 3502.
8.
Zurück zum Zitat Garin E, Laffont S, Rolland Y, Olivié D, Lecloirec J, Herry JY, et al. Safe radiation exposure of medical personnel using simple radioprotection means while administering 131I-lipiodol therapy for hepatocellular carcinoma. Nucl Med Commun. 2003;24:671–8.CrossRefPubMed Garin E, Laffont S, Rolland Y, Olivié D, Lecloirec J, Herry JY, et al. Safe radiation exposure of medical personnel using simple radioprotection means while administering 131I-lipiodol therapy for hepatocellular carcinoma. Nucl Med Commun. 2003;24:671–8.CrossRefPubMed
10.
Zurück zum Zitat Garin E, Lenoir L, Rolland Y, Edeline J, Mesba H, Laffont S, et al. 99mTc-MAA SPECT/CT based dosimetry accurately predicts tumour response and survival in HCC patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53(2):255–63.CrossRefPubMed Garin E, Lenoir L, Rolland Y, Edeline J, Mesba H, Laffont S, et al. 99mTc-MAA SPECT/CT based dosimetry accurately predicts tumour response and survival in HCC patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53(2):255–63.CrossRefPubMed
11.
Zurück zum Zitat Lancelot S, Guillet B, Sigrist S, Bourrelly M, Waultier S, Mundler O, et al. Exposure of medical personnel to radiation during radionuclide therapy practices. Nucl Med Commun. 2008;29(4):405–10.CrossRefPubMed Lancelot S, Guillet B, Sigrist S, Bourrelly M, Waultier S, Mundler O, et al. Exposure of medical personnel to radiation during radionuclide therapy practices. Nucl Med Commun. 2008;29(4):405–10.CrossRefPubMed
12.
Zurück zum Zitat Ginjaume M, Pérez S, Ortega X. Improvements in extremity dose assessment for ionising radiation medical applications. Radiat Prot Dosimetry. 2007;125(1-4):28–32.CrossRefPubMed Ginjaume M, Pérez S, Ortega X. Improvements in extremity dose assessment for ionising radiation medical applications. Radiat Prot Dosimetry. 2007;125(1-4):28–32.CrossRefPubMed
13.
Zurück zum Zitat Pereira MF, Alves JG, Sarmento S, Santos JA, Sousa MJ, Gouvêa M, et al. Preliminary assessment of the dose to the interventional radiologist in fluoro-CT-guided procedures. Radiat Prot Dosimetry. 2011;144(1-4):448–52.CrossRefPubMed Pereira MF, Alves JG, Sarmento S, Santos JA, Sousa MJ, Gouvêa M, et al. Preliminary assessment of the dose to the interventional radiologist in fluoro-CT-guided procedures. Radiat Prot Dosimetry. 2011;144(1-4):448–52.CrossRefPubMed
Metadaten
Titel
Occupational radiation exposure of medical staff performing 90Y-loaded microsphere radioembolization
verfasst von
Sophie Laffont
Yan Rolland
Valérie Ardisson
Julien Edeline
Marc Pracht
Samuel Le Sourd
Tanguy Rohou
Laurence Lenoir
Nicolas Lepareur
Etienne Garin
Publikationsdatum
19.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3277-1

Weitere Artikel der Ausgabe 5/2016

European Journal of Nuclear Medicine and Molecular Imaging 5/2016 Zur Ausgabe